Terpenoid Therapeutics Inc. molecule is effective prostate cancer metastasis in a mouse model

A novel small molecule in the Terpenoid Therapeutics Inc. (TTI) pipeline reduces metastases in a mouse model of prostate cancer. The results are published as a manuscript titled “Targeting geranylgeranylation reduces adrenal gland tumor burden in a murine model of prostate cancer metastasis,” which recently appeared in the journal Clinical & Experimental Metastasis. Dr. Ray Hohl, Director of the Penn State Cancer Institute is the senior author. The data shows a 54% reduction in total adrenal tumor burden as compared to untreated controls. The innovative TTI compound affects an important signaling pathway which serves as a biomarker in these experiments.

Get the full article…

Bookmark the permalink.

Comments are closed.